Showing 2951-2960 of 5621 results for "".
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- New Report Calls for a National Eye Care Plan for England to Address Surging Patient Demandhttps://modernod.com/news/new-report-calls-for-a-national-eye-care-plan-for-england-to-address-surging-patient-demand/2482003/As part of Westminster Eye Health Day, stakeholders and experts from across the eye health sector have launched a new report laying out action required to improve eye care for patients in England. The initiative is led by "The Eyes Have It," a partnership of Macular Society, Fight
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho
- Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officerhttps://modernod.com/news/ace-vision-group-names-rob-kissling-md-as-chief-medical-officer-1/2481938/Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology.
- Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/Pantheon Vision has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI), a non-profit organization singularly focused on eradicating corneal blindness with an emphasis on low- and middle-income countries. The funding will be us
- Study Shows Efficient AAV Delivery of Large Genes Using ViGeneron's REVeRT Technologyhttps://modernod.com/news/study-shows-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology-1/2481913/ViGeneron announced a peer-reviewed publication in
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Alcon: Cataract Surgery with AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependencehttps://modernod.com/news/alcon-cataract-surgery-with-acrysof-iq-vivity-iols-demonstrates-sustained-high-patient-satisfaction-and-reduced-spectacle-dependence/2481819/Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post-cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL). Data from